Search This Blog

Thursday, March 10, 2022

Moderna Starts Phase 2 Study of Omicron-Specific Bivalent Booster

 Moderna's Omicron-specific bivalent booster candidate (mRNA-1273.214) combines Moderna's Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)

Moderna expects to enroll approximately 375 participants in the U.S.

https://finance.yahoo.com/news/moderna-announces-first-participant-dosed-132300840.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.